Seltene Differentialdiagnosen beim Ulcus cruris venosum

Chronische Wunden stellen weltweit ein zunehmendes medizinisches und ökonomisches Problem dar. Die am häufigsten auftretenden chronischen Wunden manifestieren sich bei mehr als der Hälfte der Patient*innen als gefäßbedingte Ulzerationen. Die Ursachen für ein Ulcus cruris sind jedoch vielfältig. Insbesondere im dermatologischen Bereich werden häufig Patient*innen mit selteneren Ursachen für Unterschenkelulzerationen vorstellig. In diesem Artikel legen wir den Fokus auf seltene Differenzialdiagnosen des Ulcus cruris venosum (UCV).

Abstract

Chronic wounds have become a common reason for treatment in both inpatient and outpatient settings. Many patients are often referred to specialized care or wound centers after a therapy- refractory course. In Germany, the primary medical disciplines managing chronic wounds are general practitioners, dermatologists and surgeons. Current global literature offers few and sometimes contradictory data on the incidence and prevalence of various wound types. However, dermatological practices frequently encounter patients with venous leg ulcers (Ulcus cruris), which are descriptively wounds located in the lower leg area. These ulcers result from a diverse group of underlying conditions. For effective long-term therapy, it is crucial to fully diagnose and treat the underlying causes of the wounds. The recently published S3 guideline on the local therapy of hard-to-heal chronic wounds emphasizes the importance of medical history and response to previous treatments A vital component of the initial patient contact is a wound-specific medical history, which can provide clues about the causes of the wound. Numerous publications have shown that vascular diseases are responsible for over 50% of chronic lower leg ulcer cases. The most common is venous leg ulcer, accounting for 40–60% of cases depending on the patient population. This is followed by arterial leg ulcers (15–30%) and mixed venous-arterial ulcers. Körber et al. highlighted rarer causes of leg ulcers in a survey of wound experts and data from over 31000 patients. These rarer causes include pyoderma gangrenosum, necrobiosis lipoidica, vasculitis, hypertensive leg ulcer (Martorell), neoplastic ulcers, livedoid vasculopathy, calciphylaxis, and drug-induced ulcers. Given the complex pathogenetic relationships, interdisciplinary collaboration in investigating wound causes is crucial. To enhance understanding and presentation of these rare causes, we will discuss the key details of these conditions.

In dermatology, patients with rarer causes of chronic lower leg ulcers often present themselves. Depending on the literature, up to 25% of cases involve non-vascular lower leg ulcers.

Schlüsselwörter

Unterschenkelulzerationen - Pyoderma gangraenosum - Necrobiosis lipoidica - Vaskulitis - Livedovaskulopathie - Ulcus cruris hypertonicum - Medikamenten-assoziierte Unterschenkelulzerationen - Kalziphylaxie

Keywords

chronic leg ulcer - venous leg ulcer - rare causes of leg ulcerations - pyoderma gangrenosum - vasculitis

Publication History

Article published online:
14 October 2024

• Literatur

• 1 Manu C, Lacopi E, Bouillet B. et al. Delayed referral of patients with diabetic foot ulcers across Europe: patterns between primary care and specialised units. J Wound Care 2018; 27: 186-192
• 2 Falanga V, Isseroff RR, Soulika AM. et al. Chronic wounds. Nat Rev Dis Primers 2022; 8: 50
• 3 (Hrsg.) D. Lokaltherapie schwerheilender und/oder chronischer Wunden aufgrund von peripherer arterieller Verschlusskrankheit, Diabetes mellitus oder chronisch venöser Insuffizienz. . AWMF-Register-Nr: 091/001 2023; Version 2.1. Stand 11.09.2023.
• 4 Dissemond J. ABCDE-Regel der Diagnostik chronischer Wunden. J Dtsch Dermatol Ges 2017; 15: 732-734
• 5 Rabe E, Guex JJ, Puskas A. et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31: 105-115
• 6 Korber A, Klode J, Al-Benna S. et al. Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey. J Dtsch Dermatol Ges 2011; 9: 116-121
• 7 Maronese CA, Pimentel MA, Li MM. et al. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. Am J Clin Dermatol 2022; 23: 615-634
• 8 Flora A, Kozera E, Frew JW. Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease. Exp Dermatol 2022; 31: 498-515
• 9 Jockenhofer F, Wollina U, Salva KA. et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 2019; 180: 615-620
• 10 Yamamoto T, Yamasaki K, Yamanaka K. et al. Clinical guidance of pyoderma gangrenosum 2022. J Dermatol 2023; 50: e253-e275
• 11 Reid SD, Ladizinski B, Lee K. et al. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol 2013; 69: 783-791
• 12 Naumowicz M, Modzelewski S, Macko A. et al. A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation. Int J Mol Sci 2024; 25
• 13 Peckruhn M, Tittelbach J, Elsner P. Update: Treatment of necrobiosis lipoidica. J Dtsch Dermatol Ges 2017; 15: 151-157
• 14 Janßen S, Jansen TM. Ulcerated necrobiosis lipoidica successfully treated with tofacitinib. Int J Dermatol 2022; 61: 739-741
• 15 Karppinen JJ, Kallio M, Lappalainen K. et al. Clinical characteristics of Martorell hypertensive ischaemic leg ulcer. J Wound Care 2023; 32: 797-804
• 16 Kraus LF, Elsharkawi-Welt K, Peters T. et al. Diagnostic Challenge of Bilateral Martorell Hypertensive Ischaemic Leg Ulcers. Acta Derm Venereol 2021; 101: adv00457
• 17 Pastor D, Toutous Trellu L. Martorell hypertensive ischemic ulcer: an atypical wound to know. Rev Med Suisse 2020; 16: 636-639
• 18 Shanmugam VK, Angra D, Rahimi H. et al. Vasculitic and autoimmune wounds. J Vasc Surg Venous Lymphat Disord 2017; 5: 280-292
• 19 Shavit E, Alavi A, Sibbald RG. Vasculitis-What Do We Have to Know? A Review of Literature. Int J Low Extrem Wounds 2018; 17: 218-226
• 20 Hoff NP, Homey B. Calciphylaxis. Pathogenesis and therapy. Hautarzt 2011; 62: 509-515
• 21 Renner R, Dissemond J, Goerge T. et al. Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis. J Eur Acad Dermatol Venereol 2017; 31: 1884-1889
• 22 Weishaupt C, Strölin A, Kahle B. et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 2016; 3: e72-e79
• 23 Schiffmann ML, Dissemond J, Erfurt-Berge C. et al. German S1 guideline: diagnosis and treatment of livedovasculopathy. J Dtsch Dermatol Ges 2021; 19: 1668-1678
• 24 Misciali C, Dika E, Fanti PA. et al. Frequency of malignant neoplasms in 257 chronic leg ulcers. Dermatol Surg 2013; 39: 849-854
• 25 Valesky EM, Hach-Wunderle V, Protz K. et al. Diagnosis and treatment of venous leg ulcers: S2k Guideline of the German Society of Phlebology and Lymphology (DGPL) e.V. J Dtsch Dermatol Ges 2024; 22: 1039-1051
• 26 Dissemond J. Medications. A rare cause for leg ulcers. Hautarzt 2011; 62: 516-523
• 27 Akanay-Diesel S, Hoff NP, Kürle S. et al. Sunitinib induced pyoderma gangrenosum-like ulcerations. Eur J Med Res 2011; 16: 491-494
• 28 Best PJ, Daoud MS, Pittelkow MR. et al. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128: 29-32
• 29 Soya E, Makowski C, Blaise S. Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?. Int Wound J 2019; 16: 897-902